This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dispenzieri A, Wiseman GA, Lacy MQ, Litzow MR, Anderson PM, Gastineau DA et al. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia 2005; 19: 118–125.
Durrie B, Salmon S . A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36: 842–854.
Morton J, Hutchins C, Durrant S . Granulocyte-colony-stimulating factor (G-CSF) primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF mobilized peripheral blood stem cells. Blood 2001; 98: 3186–3191.
Bartlett M, Webb M, Durrant S, Morton J, Allison A, MacFarlane D . Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies. Eur J Nucl Med 2002; 29: 1470–1477.
MacFarlane D, Durrant S, Bartlett M, Allison R, Morton J . 153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies. Nucl Med Commun 2002; 23: 1099–1106.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kennedy, G., Durrant, S., Butler, J. et al. Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen. Leukemia 19, 879–880 (2005). https://doi.org/10.1038/sj.leu.2403698
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403698